VERAXA Biotech Advances BiTAC-TCE Development with Positive Regulatory Feedback from Germany

VERAXA Biotech AG (NASDAQ: VRXA) has taken a significant step forward in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI). The regulatory feedback supports the company's proposed development strategy for its lead BiTAC(R)-TCE program, providing early guidance on biological rationale, safety assessments, and non-clinical development plan. This milestone is crucial as it helps reduce development uncertainty by offering greater clarity before advancing toward clinical studies (https://ibn.fm/zBiDU).

The BiTAC(R)-TCE platform is designed to create bispecific T-cell engagers that harness the immune system to target cancer cells. VERAXA's lead candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The positive regulatory feedback from PEI validates the company's approach and paves the way for more efficient clinical development.

VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The company is focused on advancing next-generation antibody therapeutics for cancer, leveraging its proprietary platforms to address significant unmet medical needs.

The latest regulatory milestone follows continued progress in manufacturing and development. By engaging with regulatory authorities early in the development process, VERAXA aims to align its strategies with regulatory expectations, potentially accelerating timelines and improving the likelihood of successful clinical outcomes. This proactive approach is particularly important for novel therapeutic platforms like BiTAC(R)-TCE, where regulatory guidance can help navigate complex safety and efficacy considerations.

VERAXA Biotech is an emerging leader in designing novel cancer therapies, and this regulatory feedback marks an important inflection point as the company transitions from preclinical to clinical development. Investors and stakeholders can find the latest news and updates relating to VRXA in the company's newsroom at https://ibn.fm/VRXA.